Transgene to present new positive preliminary Phase I Clinical data
Category: dates
Availability of Transgene’s 2021 Universal Registration Document
Availability of Transgene’s universal registration document
Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
Availability of Preparatory documents
Transgene’s Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman
Transgene’s board of directors strengthens its governance
Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022
Transgene confirms the potential of its two innovative platforms
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
Transgene to present new positive preliminary Phase I data on TG4050
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
Transgene and BioInvent Announce Poster Presentation on BT-001
Transgene appoints Steven Bloom as Chief Business Officer
Transgene appoints Steven Bloom as Chief Business Officer
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
Semmrich M, Marchand J, Fend L, et alJournal for ImmunoTherapy of Cancer Download the publication herePublication